WOCKPHARMA2023-01-012023-03-31 WOCKPHARMA2023-01-012023-03-31 WOCKPHARMA2023-01-012023-03-31in-bse-fin:OneOperatingExpenses01Member WOCKPHARMA2023-01-012023-03-31in-bse-fin:OneOperatingExpenses02Member WOCKPHARMA2023-01-012023-03-31in-bse-fin:FourOperatingExpenses01Member WOCKPHARMA2023-01-012023-03-31in-bse-fin:FourOperatingExpenses02Member WOCKPHARMA2023-03-31 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 532300 WOCKPHARMA NA Wockhardt Limited Equity 2022-04-01 2023-03-31 2023-05-26 2023-05-19 INR Crores Yearly 11:45:00 17:00:00 2023-05-26 2023-05-26 true Cash Flow Indirect Declaration of unmodified opinion Single segment Pharmaceuticals 2023-01-01 2023-03-31 Audited Standalone 2910000000.00 290000000.00 3200000000.00 600000000.00 310000000.00 230000000.00 520000000.00 580000000.00 450000000.00 1550000000.00 4240000000.00 -1040000000.00 -1850000000.00 -2890000000.00 0.00 100000000.00 100000000.00 0.00 -2990000000.00 0.00 0.00 0.00 0.00 -2990000000.00 50000000.00 -2940000000.00 0.00 0.00 720000000.00 5 -20.80 -20.80 0.00 0.00 -20.80 -20.80 Notes To Standalone Results :- 1) The results were reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on May 26, 2023. The Statutory Auditors have expressed an unmodified audit opinion with respect to the Audited Financial Results of the Company for the quarter/year ended March 31, 2023. 2) (a)The Company had accounted for a contract asset of Rs. 50 crores pursuant to a contract manufacturing agreement. The Customer is yet to fulfil its contractual obligations and commitments. Though, the Company is pursuing various options and taking necessary actions related to this matter, given the uncertainty, Company has provided for this contract asset and has disclosed it as 'Exceptional items'. (b)The Company had received advances for supply of goods from Wockhardt Bio AG, a majorly held foreign subsidiary of the Company, of which USD 89 million had been outstanding as at March 31, 2022.  In accordance with the direction of Reserve Bank of India (RBI) / Authorised Dealer (AD) Bank, such advances were supposed to be adjusted only against supply of goods by the Company. Accordingly, this  advance amount received was accounted at the historical transaction exchange rate in accordance with Ind AS 21- 'The Effects of Changes in Foreign Exchange Rates'   The Company, as part of normal business, has also been providing services including but not limited to R&D services and assignment of rights over its new chemical entities (NCE) to the aforesaid foreign subsidiary and has outstanding receivables of USD 113 million.  Since the Company has not been able to supply the goods, the Company has received an approval from RBI/ AD on March 10, 2023, for adjustment of the aforesaid advance with these outstanding receivables. Pursuant to this, Company has recognised an exchange loss of Rs. 185 crore on the settlement of the advance and receivables of USD 89 million under 'Exceptional items'. Given that these receivables and advance liability are eliminated on consolidation, this settlement does not have any impact on the consolidated financial results of the Group for the current period. 3) Subsequent to March 31, 2023, the terms of borrowings of Rs. 600 crores from related parties, which were repayable on demand have been revised and now the repayment tenure for such borrowings have been extended to March 31, 2025, with an option to the Company to further renew the loan basis Company’s assessment of cash flows and liquidity position on that date. However, such loans have been reported in the balance sheet as at March 31, 2023 as current liability. 4) Revenue for the quarter and year ended March 31, 2022 includes Rs. 152 crore for assignment of intellectual property rights to one of its Subsidiary. The transaction has been eliminated in the Consolidated financial statements. 5) Basic and diluted earnings per share for the quarter and year ended March 31, 2022 have been adjusted appropriately for the bonus element in respect of issue of equity shares by way of rights issue that was completed during the quarter ended March 31, 2022. 6) During the quarter ended March 31, 2023 , the Company has allotted 28,170 (Year to date 28,170 ) Equity shares of face value of Rs. 5/- each pursuant to exercise of employee stock options. 7) Other income for the quarter and year ended March 31, 2023 includes profit on sale of Properties amounting to Rs 29 crore. 8) Figures for the quarter ended March 31, 2023 and March 31, 2022 are the balancing figures between the audited figures of the full financial year and the reviewed figures upto the third quarter of the relevant financial year. 9) The Company is exclusively into Pharmaceutical business Segment. Single segment 2022-04-01 2023-03-31 Audited Standalone 10720000000.00 670000000.00 11390000000.00 2000000000.00 1710000000.00 300000000.00 2400000000.00 2290000000.00 1860000000.00 3610000000.00 14170000000.00 -2780000000.00 -2350000000.00 -5130000000.00 0.00 -470000000.00 -470000000.00 0.00 -4660000000.00 0.00 0.00 0.00 0.00 -4660000000.00 40000000.00 -4620000000.00 0.00 0.00 720000000.00 5 16810000000.00 -32.40 -32.40 0.00 0.00 -32.40 -32.40 Exchange fluctuation loss, net 580000000.00 Other expenses 970000000.00 Exchange fluctuation loss, net 0.00 Other expenses 3610000000.00 15570000000.00 560000000.00 0.00 0.00 680000000.00 7670000000.00 0.00 0.00 2970000000.00 0.00 0.00 630000000.00 3600000000.00 2500000000.00 1990000000.00 32570000000.00 3630000000.00 0.00 5510000000.00 40000000.00 330000000.00 0.00 1200000000.00 7080000000.00 0.00 2250000000.00 12960000000.00 1790000000.00 0.00 47320000000.00 720000000.00 16810000000.00 17530000000.00 17530000000.00 120000000.00 0.00 3150000000.00 3270000000.00 260000000.00 0.00 0.00 0.00 3530000000.00 16080000000.00 5570000000.00 3460000000.00 25110000000.00 880000000.00 250000000.00 20000000.00 0.00 26260000000.00 0.00 0.00 29790000000.00 47320000000.00 Notes for Assets and Liabilities: 1. Property, Plant and Equipment includes Right of use assets amounting to Rs. 371 crore. 2. Non-current Investment consists of (a) Investments in subsidiaries Rs. 297 crore and (b) Other investments Rs. 0.45 crore. 3. Other non-current assets includes Non-current tax assets (net) amounting to Rs. 94 crore. 4. Other non-current financial liabilities consists Lease liabilities amounting to Rs. 315 crore. 5. Trade payables, current consists of (a) Total outstanding dues of Micro enterprises and Small enterprises amounting to Rs. 45 crore and (b) Total outstanding dues of creditors other than micro enterprises and small enterprises amounting to Rs. 537 crore. 6. Other current financial liabilities include Lease liabilities amounting to Rs. 78 crore. 7. Non-current assets classified as held for sale represents Assets classified as held for sale. Notes for Financial Results: 1. EPS for the quarter ended March 31, 2023 is not annualised. Notes to Cash Flow Statements 1. Other adjustments for cash items consists of Provision for contract asset Rs. 50 crore, Reversal of allowance for expected creditt loss and bad debts Rs. 14 crore, Loss on assets sold/write off of fixed assets (net) Rs. 29 crore and Liabilities no longer required written back Rs. 3 crore. 3. Adjustments for unrealised foreign exchange losses and gain consist of Net foreign exchange fluctuation, loss/(gain), net Rs. 17 crore. 4. Proceeds from issuing shares consist of transaction cost related to Right Issue Rs. 3 crore. 5. Proceeds from exercise of stock option of is Rs. 0.01 crore. 6. Proceeds from borrowing consists of loan from Related Parties Rs. 328 crore and Short term borrowings (net) Rs. 67 crore. 7. Repayment of borrowings consist of Repayment of long term borrowings Rs.252 crore and Repayment of loan taken from Related Parties Rs. 116 crore. 8. Other inflows (outflows) of cash consists of Finance cost paid Rs. 181 crore. 9. Aggregated/segregated in accordance with the prescribed format and to the extent is the requirement of the accounting standard. 2290000000.00 240000000.00 7590000000.00 0.00 -290000000.00 0.00 0.00 0.00 0.00 -290000000.00 0.00 -5690000000.00 0.00 1860000000.00 0.00 0.00 0.00 0.00 0.00 170000000.00 0.00 40000000.00 10000000.00 0.00 0.00 0.00 0.00 40000000.00 0.00 5890000000.00 760000000.00 0.00 0.00 0.00 50000000.00 0.00 710000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 390000000.00 0.00 0.00 0.00 0.00 470000000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 20000000.00 0.00 30000000.00 0.00 -30000000.00 0.00 0.00 -30000000.00 0.00 0.00 0.00 0.00 0.00 3950000000.00 3680000000.00 0.00 790000000.00 0.00 0.00 0.00 -1810000000.00 -2360000000.00 -1680000000.00 0.00 -1680000000.00 1720000000.00 40000000.00 50000000.00 40000000.00 0.00 0.00 0.00 0.00